HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysisSantam Chakraborty, Debdeep Dey, Rosina Ahmed et al.|Radiotherapy and Oncology|2022Cited by 42
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trialSanjoy Chatterjee, Santam Chakraborty, Selvamani Backianathan et al.|Trials|2020Cited by 29
701: Cardiac safety of ultra-Hypofractionated RT in the HYPORT Adjuvant randomized trial (NCT03788213)Sanjoy Chatterjee, HYPORT Adjuvant Trialists Group, Santam Chakraborty et al.|Radiotherapy and Oncology|2024Cited by 1